Biorestorative Therapies, Inc. (NASDAQ:BRTX) Shares Shorted: Short Interest Down 69.2% in September

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totaling 11,586 shares, a drop of 69.2% from the August 31st total of 37,641 shares. Based on an average daily volume of 40,553 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.0% of the company’s shares are short sold.

Biorestorative Therapies Trading Up 1.6%

Shares of NASDAQ BRTX traded up $0.04 during trading hours on Friday, reaching $2.55. The stock had a trading volume of 27,998 shares, compared to its average volume of 34,144. Biorestorative Therapies has a 52-week low of $2.44 and a 52-week high of $34.60. The firm has a market cap of $3.52 million, a price-to-earnings ratio of -0.12 and a beta of 0.83. The business’s fifty day moving average price is $3.97 and its two-hundred day moving average price is $5.30.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, August 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Biorestorative Therapies Company Profile

BioRestorative Therapies, Inc is a biotechnology company focused on developing regenerative medicine products using cell-based therapies. The company’s research programs are aimed primarily at treating musculoskeletal disorders and conditions associated with metabolic health.

Its principal product candidate is BRTX-100, an autologous cell therapy being developed for painful degenerative disc disease. The treatment is designed to use a patient’s own bone marrow-derived cells, which are processed and expanded before being administered to the affected spinal disc.